New research shows Vype ePen 3 highly preferred by vapers

November 24, 2020

New research published today shows that Vype ePen 3, BAT's flagship vapour product, can provide smokers with similar levels of nicotine as standard cigarettes and, with exclusive use, could be used to avoid many of the risks associated with smoking.

The study, which has been published in Scientific Reports, compared Vype ePen 3 and Vype ePen 2, containing e-liquids with a variety of nicotine strengths, to combustible cigarettes. It assessed each product's ability to deliver nicotine and how the different concentrations and delivery devices combined to affect user likability and preference.

Results from the study show that Vype ePen 3 was superior to Vype ePen 2 for nicotine delivery and user satisfaction, with the newer device gaining a liking score almost double that of its predecessor.

The study showed that the maximum concentration of nicotine in the blood after using the Vype ePen 3 (18mg/mL protonated nicotine) was more than twice that achieved using Vype ePen 2 (18mg/mL unprotonated nicotine).

BAT is committed to building A Better Tomorrow by reducing the health impact of its business through providing a range of enjoyable and lower risk products. The company aims to have 50 million users of its non-combustible products by 2030 and today's announcement demonstrates the company's commitment to innovation is delivering a continually improving portfolio of products that provides an enhanced consumer experience.

Dr David O'Reilly, BAT's Director of Scientific Research said:

"The results of this study are very impressive and show how through continued innovation and research we have improved our understanding of what consumers want, but importantly how to deliver this with our products.

"We know that for many smokers, nicotine levels are an important factor in choosing a vaping product, particularly when initially switching. They want it to work for them, delivering the nicotine they want in a device they like. We think we have achieved this with Vype ePen 3 and hope that through continued product innovation we can encourage and enable those who would otherwise continue to smoke to switch to a reduced-risk alternative which has been scientifically substantiated."

This was a randomised study during which each participant was given 8 different options. The subjects were all current smokers, who were dual users of cigarettes and vapour products. Over a period of 9 days, each morning, following an overnight wash-out period (12hrs), participants used one of the available options. The level of nicotine in the blood (plasma) was assessed before, during and after their use. These data were used to evaluate changes in nicotine concentration in the user. Participants were also asked to rate their liking of each product after use.

BAT's Vype ePen 3 was designed to provide consumers with the same high-quality product they expect but to deliver an improved user experience. Early generations of e-cigarettes often delivered lower nicotine yields than combustible cigarettes, which many associate with a lower acceptance or continuation by user.

BAT has continued to innovate the Vype ePen to develop its nicotine delivery capabilities and enhance user satisfaction. This study was designed to validate the acceptance and preference of consumers who frequently use cigarettes and vapour products.

One of the improved design features of the Vype ePen 3 is its increased power, which, together with its ability to deliver a nicotine salt, known as protonated nicotine, provides a higher aerosol mass, resulting in a greater absorption of nicotine. The ability to increase the aerosol mass also reduces the potential for irritation of the pharynx, which has been associated with higher levels of unprotonated nicotine.

R&D at British American Tobacco

Related Nicotine Articles from Brightsurf:

Nicotine vapour more rewarding for adolescents than adults
University of Guelph researchers are the first to discover that adolescents react differently to e-cigarette vapour than adults.

Understanding the link between nicotine use and misuse of 'benzos'
Lately, misuse of prescription benzodiazepines (such as alprazolam or Xanax, and diazepam or Valium) has been linked to nicotine use.

Popular electronic cigarette may deliver nicotine more effectively than others
When it comes to nicotine delivery, not all electronic cigarettes are created equally, according to Penn State researchers.

Fetal nicotine exposure harms breathing in infants
Exposure to nicotine during development inhibits the function of neurons controlling the tongue, according to research in newborn rats recently published in eNeuro.

Diabetes drug relieves nicotine withdrawal
A drug commonly used to treat Type II diabetes abolishes the characteristic signs of nicotine withdrawal in rats and mice, according to new research published in JNeurosci.

The nicotine in e-cigarettes appears to impair mucus clearance
E-cigarette vaping with nicotine appears to hamper mucus clearance from the airways, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Truth telling about tobacco and nicotine
In 'Truth Telling about Tobacco and Nicotine,' PRC researchers explain that, although there is agreement among researchers about evidence that vaping can be less harmful than combustible cigarettes, the tobacco control community remains divided about how to communicate -- or even whether to communicate -- information about the relative risks of tobacco and nicotine products.

This is a neuron on nicotine
Newly developed sensors visually illustrate how nicotine affects cells from the inside out.

New data suggests nicotine while pregnant alters genes
A University of Houston biomedical research team is reporting that a possible cure for addiction may be found by following the pathways of significantly altered dopamine neurons in newborns who were chronically exposed to nicotine in utero.

Ex-smokers might be better off with high rather than low nicotine e-cigs
Vapers using low rather than high nicotine e-cigarettes may be using their devices more intensely, potentially increasing the risk of exposure to toxins in the vapour, according to new research funded by Cancer Research UK and published in Addiction today.

Read More: Nicotine News and Nicotine Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to